Plain-English translation of NCT07275788 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new treatment called , which consists of human kidney progenitor cells designed to help repair kidney injury. Researchers want to see if this treatment is safe and well-tolerated in people who have type 2 diabetes and chronic kidney disease. The study will involve about 15 participants, some of whom will receive the medication and others a placebo.
Kidney damage from diabetes is a serious problem that can eventually lead to kidney failure and the need for dialysis. Researchers are exploring whether this new treatment could help repair damaged kidney tissue and slow or prevent further decline in kidney function.
You likely qualify if…
You likely don't qualify if…
Participants will receive either the kidney cell treatment or a placebo, delivered through an injection directly into the kidney during a procedure. The study uses a dose-escalation design, meaning some participants will receive different amounts of the treatment to test safety and tolerability. You would need to attend multiple visits for monitoring and examinations to track how your kidneys respond to the treatment.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China